title: Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol.
abstract: The naturally occurring polyphenol resveratrol (RES) has attracted increasing attention in recent years due to its antioxidant, anti-inflammatory, and anticancer activity. However, resveratrol's promising potential as a nutraceutical is hindered by its poor aqueous solubility, which limits its biological activity. Here we show that encapsulating resveratrol in colloidal mesoporous silica nanoparticles (MCM-48-RES) enhances its saturated solubility by ∼95% and increases its in vitro release kinetics compared to pure resveratrol. MCM-48-RES showed high loading capacity (20% w/w) and excellent encapsulation efficiency (100%). When tested against HT-29 and LS147T colon cancer cell lines, MCM-48-RES-mediated in vitro cell death was higher than that of pure resveratrol, mediated via the PARP and cIAP1 pathways. Finally, MCM-48-RES treatment also inhibited lipopolysaccharide-induced NF-κB activation in RAW264.7 cells, demonstrating improved anti-inflammatory activity. More broadly, our observations demonstrate the potential of colloidal mesoporous silica nanoparticles as next generation delivery carriers for hydrophobic nutraceuticals.
authors.affiliation: The School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia.
authors.forename: Natalie
authors.initials: N
authors.lastname: Summerlin
authors.affiliation: The School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Qu
authors.affiliation: The School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia.
authors.forename: Naisarg
authors.initials: N
authors.lastname: Pujara
authors.affiliation: Mucosal Diseases Group, Mater Research Institute-The University of Queensland, Translational Research Institute, 37 Kent St., Woolloongabba, QLD 4102, Australia.
authors.forename: Yong
authors.initials: Y
authors.lastname: Sheng
authors.affiliation: Mucosal Diseases Group, Mater Research Institute-The University of Queensland, Translational Research Institute, 37 Kent St., Woolloongabba, QLD 4102, Australia.
authors.forename: Siddharth
authors.initials: S
authors.lastname: Jambhrunkar
authors.affiliation: Mucosal Diseases Group, Mater Research Institute-The University of Queensland, Translational Research Institute, 37 Kent St., Woolloongabba, QLD 4102, Australia.
authors.forename: Michael
authors.initials: M
authors.lastname: McGuckin
authors.affiliation: The School of Pharmacy, The University of Queensland, Brisbane, QLD 4072, Australia; Mucosal Diseases Group, Mater Research Institute-The University of Queensland, Translational Research Institute, 37 Kent St., Woolloongabba, QLD 4102, Australia. Electronic address: a.popat@uq.edu.au.
authors.forename: Amirali
authors.initials: A
authors.lastname: Popat
mesh_terms: D000818:Animals; D002152:Calorimetry, Differential Scanning; D045744:Cell Line, Tumor; D003102:Colloids / Q000737:chemistry*; D065546:Drug Liberation; D006801:Humans; D051379:Mice; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D016062:Porosity; D000067996:RAW 264.7 Cells; D000077185:Resveratrol; D012822:Silicon Dioxide / Q000737:chemistry*; D012995:Solubility; D013267:Stilbenes / Q000494:pharmacology*; D013818:Thermogravimetry; D014961:X-Ray Diffraction
chemical_list: D003102:Colloids; D013267:Stilbenes; D012822:Silicon Dioxide; D000077185:Resveratrol
keywords: Anti-inflammatory; Anticancer; Colorectal cancer; Mesoporous silica; Nanoparticles; Resveratrol